We can help de-risk decision making on potential investments increasing the likelihood of success. We specialise in due-diligence of new biomedical technologies.
Before you invest are your sure:
•The preclinical evidence is reproducible?
• The models/tissue samples represent the disease?
• There is an in depth biological understanding of the target?
• You know the evidence gaps and evidence strengths?
We can help pharma in multiple areas of decision making. We can perform literature reviews for new areas of interest, identify evidence gaps and aid in the assessment of new pre-clinical models or markers
Combining systematic review with expertise in biomedical science we are uniquely placed to help inform reviews or evaluations with a deeper understanding of the underlying science. These skills are essential with the movement toward precision medicine
We have a long background in academia and our aims are to improve scientific reporting, improve reproducibility, support open science and improve clinical translation. We can provide expertise in evidence based decision making & systematic review. We are uniquely placed in these two research fields. We are interested in continuing to collaborate with academic partners